QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
NASDAQ:KALA

Kala Pharmaceuticals - KALA Stock Forecast, Price & News

$19.65
+0.68 (+3.58%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$18.00
$20.92
50-Day Range
$3.67
$42.09
52-Week Range
$3.54
$97.00
Volume
953,803 shs
Average Volume
2.29 million shs
Market Capitalization
$33.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$61.75

Kala Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
214.2% Upside
$61.75 Price Target
Short Interest
Healthy
17.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.35
Upright™ Environmental Score
News Sentiment
0.87mentions of Kala Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$7,364 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($17.80) to ($19.67) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars

Medical Sector

280th out of 1,055 stocks

Pharmaceutical Preparations Industry

134th out of 519 stocks


KALA stock logo

About Kala Pharmaceuticals (NASDAQ:KALA) Stock

Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Receive KALA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KALA Stock News Headlines

Here’s Why Sotera Health Company Stock Just Doubled in a Day (KALA)
Sotera Health Company (NASDAQ: SHC) is a leading global provider of mission-critical sterilization solutions, lab testing, and advisory services.
Kala Pharmaceuticals Up 400% In The Past Month, What's Next ?
Kala pharmaceuticals underwent a massive rally over the past few days, and by all indications, the stock price is now headed toward a bottom.
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Nasdaq Down 100 Points; Kala Pharmaceuticals Shares Spike Higher
Why Is Kala Pharmaceuticals (KALA) Stock Soaring 240%?
See More Headlines
Receive KALA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KALA Company Calendar

Last Earnings
11/08/2022
Today
1/27/2023
Next Earnings (Estimated)
4/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KALA
Employees
192
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$61.75
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$37.50
Forecasted Upside/Downside
+214.2%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-142,600,000.00
Net Margins
-1,383.91%
Pretax Margin
-1,383.91%

Debt

Sales & Book Value

Annual Sales
$11.24 million
Book Value
$12.83 per share

Miscellaneous

Free Float
1,462,000
Market Cap
$33.54 million
Optionable
Optionable
Beta
-1.57

Key Executives

  • Mark T. IwickiMark T. Iwicki
    Chairman & Chief Executive Officer
  • Todd BazemoreTodd Bazemore
    President & Chief Operating Officer
  • Mary E. ReumuthMary E. Reumuth
    Chief Financial Officer
  • Romulus Kim BrazzellRomulus Kim Brazzell
    Chief Medical Officer, Head-Research & Development
  • Eric L. Trachtenberg
    Secretary & Chief Compliance Officer













KALA Stock - Frequently Asked Questions

Should I buy or sell Kala Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" KALA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KALA, but not buy additional shares or sell existing shares.
View KALA analyst ratings
or view top-rated stocks.

What is Kala Pharmaceuticals' stock price forecast for 2023?

3 brokerages have issued 12-month target prices for Kala Pharmaceuticals' shares. Their KALA share price forecasts range from $37.50 to $100.00. On average, they expect the company's stock price to reach $61.75 in the next year. This suggests a possible upside of 204.6% from the stock's current price.
View analysts price targets for KALA
or view top-rated stocks among Wall Street analysts.

How have KALA shares performed in 2023?

Kala Pharmaceuticals' stock was trading at $38.15 at the beginning of the year. Since then, KALA stock has decreased by 46.9% and is now trading at $20.27.
View the best growth stocks for 2023 here
.

Are investors shorting Kala Pharmaceuticals?

Kala Pharmaceuticals saw a drop in short interest during the month of January. As of January 15th, there was short interest totaling 236,300 shares, a drop of 52.2% from the December 31st total of 494,700 shares. Based on an average daily trading volume, of 2,300,000 shares, the short-interest ratio is presently 0.1 days. Currently, 17.6% of the company's shares are sold short.
View Kala Pharmaceuticals' Short Interest
.

When is Kala Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023.
View our KALA earnings forecast
.

How were Kala Pharmaceuticals' earnings last quarter?

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) released its earnings results on Tuesday, November, 8th. The company reported $19.25 earnings per share for the quarter, beating analysts' consensus estimates of $10.75 by $8.50. The company earned $0.42 million during the quarter, compared to the consensus estimate of $62.50 million. Kala Pharmaceuticals had a negative net margin of 1,383.91% and a negative trailing twelve-month return on equity of 1,320.11%.

When did Kala Pharmaceuticals' stock split?

Shares of Kala Pharmaceuticals reverse split before market open on Friday, October 21st 2022. The 1-50 reverse split was announced on Friday, October 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What is Mark Iwicki's approval rating as Kala Pharmaceuticals' CEO?

1 employees have rated Kala Pharmaceuticals Chief Executive Officer Mark Iwicki on Glassdoor.com. Mark Iwicki has an approval rating of 100% among the company's employees. This puts Mark Iwicki in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Kala Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kala Pharmaceuticals investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Micron Technology (MU), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Amarin (AMRN), Bristol-Myers Squibb (BMY), NVIDIA (NVDA) and AbbVie (ABBV).

When did Kala Pharmaceuticals IPO?

(KALA) raised $90 million in an IPO on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

What is Kala Pharmaceuticals' stock symbol?

Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."

How do I buy shares of Kala Pharmaceuticals?

Shares of KALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kala Pharmaceuticals' stock price today?

One share of KALA stock can currently be purchased for approximately $20.27.

How much money does Kala Pharmaceuticals make?

Kala Pharmaceuticals (NASDAQ:KALA) has a market capitalization of $34.60 million and generates $11.24 million in revenue each year. The company earns $-142,600,000.00 in net income (profit) each year or ($56.25) on an earnings per share basis.

How many employees does Kala Pharmaceuticals have?

The company employs 192 workers across the globe.

How can I contact Kala Pharmaceuticals?

Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. The official website for the company is www.kalarx.com. The company can be reached via phone at (781) 996-5252, via email at hannah.deresiewicz@sternir.com, or via fax at 781-642-0399.

This page (NASDAQ:KALA) was last updated on 1/27/2023 by MarketBeat.com Staff